Small molecules in oncology:
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Berlin [u.a.]
Springer
2014
|
| Ausgabe: | 2. ed. |
| Schriftenreihe: | Recent results in cancer research
201 |
| Schlagworte: | |
| Online-Zugang: | Inhaltstext Inhaltsverzeichnis |
| Beschreibung: | XVI, 417 S. Ill., graph. Darst. 24 cm |
| ISBN: | 3642544894 9783642544897 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV041857715 | ||
| 003 | DE-604 | ||
| 005 | 20140627 | ||
| 007 | t | ||
| 008 | 140521s2014 gw ad|| |||| 00||| eng d | ||
| 015 | |a 14,N06 |2 dnb | ||
| 016 | 7 | |a 1047007568 |2 DE-101 | |
| 020 | |a 3642544894 |9 3-642-54489-4 | ||
| 020 | |a 9783642544897 |c Gb. : ca. EUR 149.79 (DE) (freier Pr.), ca. EUR 153.99 (AT) (freier Pr.), ca. sfr 186.50 (freier Pr.) |9 978-3-642-54489-7 | ||
| 024 | 3 | |a 9783642544897 | |
| 028 | 5 | 2 | |a Best.-Nr.: 86236875 |
| 035 | |a (OCoLC)881372331 | ||
| 035 | |a (DE-599)DNB1047007568 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BE | ||
| 049 | |a DE-355 |a DE-29 |a DE-19 | ||
| 082 | 0 | |a 616.994061 |2 22/ger | |
| 084 | |a XI 7000 |0 (DE-625)153024:12905 |2 rvk | ||
| 084 | |a 610 |2 sdnb | ||
| 245 | 1 | 0 | |a Small molecules in oncology |c Uwe M. Martens ed. |
| 250 | |a 2. ed. | ||
| 264 | 1 | |a Berlin [u.a.] |b Springer |c 2014 | |
| 300 | |a XVI, 417 S. |b Ill., graph. Darst. |c 24 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Recent results in cancer research |v 201 | |
| 650 | 0 | 7 | |a Cytostatikum |0 (DE-588)4068347-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Kleines Molekül |0 (DE-588)4164124-3 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 0 | 1 | |a Kleines Molekül |0 (DE-588)4164124-3 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Martens, Uwe Marc |d 1966- |0 (DE-588)132250608 |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |z 978-3-642-54490-3 |
| 830 | 0 | |a Recent results in cancer research |v 201 |w (DE-604)BV000000043 |9 201 | |
| 856 | 4 | 2 | |m X:MVB |q text/html |u http://deposit.dnb.de/cgi-bin/dokserv?id=4582318&prov=M&dok_var=1&dok_ext=htm |3 Inhaltstext |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=027302021&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-027302021 | |
Datensatz im Suchindex
| _version_ | 1809769724933832704 |
|---|---|
| adam_text |
CONTENTS
IMATINIB MESYLATE 1
CORNELIUS F. WALLER
1 INTRODUCTION 2
2 STRUCTURE AND MECHANISMS OF ACTION 4
3 PRECLINICAL DATA 5
4 CLINICAL DATA IN CML 7
4.1 PHASE I TRIALS 7
4.2 PHASE II STUDIES 8
4.3 PHASE III STUDY (IRIS TRIAL) 9
5 TREATMENT RECOMMENDATIONS FOR THE USE OF IMATINIB
IN CHRONIC PHASE CML 10
6 IMATINIB IN COMBINATION WITH OTHER DRUGS 12
7 IMATINIB: OTHER TARGETS 13
8 SIDE EFFECTS/TOXICITY 14
9 CLINICAL PHARMACOLOGY AND DRUG INTERACTIONS 17
10 BIOMARKERS 18
10.1 CML 18
10.2 GIST 18
11 SUMMARY AND PERSPECTIVES 19
REFERENCES 20
DASATINIB 27
MARKUS LINDAUER AND ANDREAS HOCHHAUS
1 INTRODUCTION 28
2 STRUCTURE AND MECHANISM OF ACTION 29
3 PRECLINICAL DATA 31
3.1 INHIBITION OF ABL 31
3.2 INHIBITION OF SRC 32
3.3 INHIBITION OF KIT 33
3.4 INHIBITION OF PLATELET-DERIVED GROWTH FACTOR RECEPTOR
(PDGFR) A AND FT TYROSINE KINASES 33
3.5 INHIBITION OF EPHRIN RECEPTOR TYROSINE KINASES 34
3.6 INHIBITION OF TEC FAMILY KINASES AND BTK 34
VII
HTTP://D-NB.INFO/1047007568
VIII CONTENTS
4 CLINICAL DATA 35
4.1 PHARMACOKINETIC PROFILE 35
4.2 CLINICAL TRIALS WITH DASATINIB 35
4.3 CLINICAL TRIALS WITH DASATINIB IN CML PATIENTS: OVERVIEW . 35
4.4 DASATINIB IN PH+ ACUTE LYMPHOBLASTIC
LEUKEMIA (PH+ ALL) 42
4.5 DASATINIB IN PHILADELPHIA-CHROMOSOME-NEGATIVE ACUTE
AND CHRONIC MYELOID DISEASES, INCLUDING
SYSTEMIC MASTOCYTOSIS 43
4.6 DASATINIB IN THE TREATMENT OF SOLID TUMORS 45
5 TOXICITY 48
6 DRUG INTERACTIONS 53
7 BIOMARKERS 54
8 SUMMARY AND PERSPECTIVES 55
REFERENCES 56
NILOTINIB 67
BENJAMIN N. OSTENDORF, PHILIPP LE COUTRE, THEO D. KIM
AND ALFONSO QUMTAS-CARDAMA
1 INTRODUCTION 68
2 STRUCTURE AND MECHANISM OF ACTION 69
3 PRECLINICAL DATA 69
4 CLINICAL DATA 70
4.1 NILOTINIB PHASE I TRIAL 70
4.2 NILOTINIB SECOND- AND THIRD-LINE THERAPY 71
4.3 NILOTINIB FIRST-LINE THERAPY 72
4.4 RESISTANCE TO NILOTINIB 73
5 TOXICITY 74
6 DRUG INTERACTIONS 76
7 BIOMARKERS 77
8 SUMMARY AND PERSPECTIVES 77
REFERENCES 78
BOSUTINIB: A NOVEL SECOND-GENERATION TYROSINE
KINASE INHIBITOR 81
SUSANNE ISFORT, GUNHILD KELLER-V. AMSBERG, PHILIPPE SCHAFHAUSEN,
STEFFEN KOSCHMIEDER AND TIM H. BRIIMMENDORF
1 STRUCTURE AND MECHANISM OF ACTION 82
1.1 CHEMICAL STRUCTURE 82
1.2 MECHANISM OF ACTION (TARGET PROFILE) 82
1.3 SRC KINASE INHIBITION 83
1.4 ABL AND BCR-ABL INHIBITION 83
CONTENTS IX
2 PRECLINICAL DATA 84
2.1 BCR-ABL-DEPENDENT DISEASES 84
2.2 POTENTIAL NEW HEMATOLOGIC DISEASES/TARGETS 86
2.3 BREAST CANCER 86
2.4 COLORECTAL CANCER 87
2.5 NON-SMALL CELL LUNG CELL CANCER 87
2.6 POLYCYSTIC KIDNEY DISEASE 87
3 CLINICAL DATA 88
3.1 BOSUTINIB IN TREATMENT-RESISTANTZ-INTOLERANT CML 88
3.2 BOSUTINIB IN CML FIRST-LINE TREATMENT 91
3.3 BOSUTINIB IN SOLID TUMORS 92
4 TOXICITY 92
5 DRUG INTERACTIONS 93
6 BIOMARKERS 93
7 SUMMARY AND PERSPECTIVES 94
REFERENCES 95
PONATINIB: A THIRD-GENERATION INHIBITOR
FOR THE TREATMENT OF CML 99
JULIUS WEHRLE, HEIKE L. PAHL AND NIKOLAS VON BUBNOFF
1 RESISTANCE TO TREATMENT IN CML 100
2 SECOND-GENERATION INHIBITORS 101
3 PONATINIB: A NEW THIRD-GENERATION INHIBITOR 101
REFERENCES 105
ERLOTINIB 109
M. STEINS, M. THOMAS AND M. GEILMER
1 INTRODUCTION 110
2 MECHANISM OF ACTION 110
3 NON-SMALL CELL LUNG CANCER 112
4 PANCREATIC ADENOCARCINOMA 115
5 HEPATOCELLULAR CARCINOMA 118
6 OTHER TUMOUR ENTITIES 120
REFERENCES 120
LAPATINIB 125
MINNA NOLTING, TANJA SCHNEIDER-MERCK AND MARTIN TREPEL
1 INTRODUCTION 126
1.1 THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY
OF TYROSINE KINASES 126
1.2 HUMAN EPIDERMAL GROWTH FACTOR RECEPTORS
AND THEIR INHIBITION IN CANCER 127
2 STRUCTURE AND MECHANISM OF ACTION 128
3 PHARMACOLOGY 130
X CONTENTS
4 RESULTS FROM CLINICAL TRIALS 130
4.1 EFFICACY IN BREAST CANCER 130
4.2 EFFICACY IN GASTROESOPHAGEAL CANCER 137
4.3 TOLERABILITY 138
5 CONCLUSION AND FUTURE PERSPECTIVES 139
REFERENCES 140
SORAFENIB: TARGETING MULTIPLE TYROSINE KINASES IN CANCER 145
JENS HASSKARL
1 INTRODUCTION 146
2 STRUCTURE AND MECHANISM OF ACTION 147
3 CLINICAL DATA 149
3.1 PHASE I 149
3.2 EXPERIENCE IN SPECIAL PATIENT POPULATIONS 149
3.3 EXPERIENCE IN PEDIATRIC PATIENTS 150
3.4 ACTIVE CLINICAL TRIALS 151
3.5 SORAFENIB IN THE TREATMENT OF RENAL CELL CANCER 151
3.6 SORAFENIB IN THE TREATMENT OF HEPATOCELLULAR CANCER 153
3.7 SORAFENIB IN THE TREATMENT OF LUNG CANCER 153
3.8 SORAFENIB IN THE TREATMENT OF BREAST CANCER 154
3.9 SORAFENIB IN THE TREATMENT OF MALIGNANT MELANOMA 154
3.10 SORAFENIB IN THE TREATMENT OF PROSTATE CANCER 154
3.11 SORAFENIB IN THE TREATMENT OF HEAD AND NECK CANCER 155
3.12 SORAFENIB IN THE TREATMENT OF OVARIAN CANCER 155
3.13 SORAFENIB IN THE TREATMENT OF BRAIN TUMORS 155
3.14 SORAFENIB IN THE TREATMENT OF THYROID CANCER 155
3.15 SORAFENIB IN THE TREATMENT OF HEMATOLOGIC DISEASES 156
4 CLINICAL SAFETY PROFILE OF SORAFENIB 157
5 CONCLUSION AND FUTURE PERSPECTIVES 157
REFERENCES 157
SUNITINIB IN THE TREATMENT OF ADVANCED SOLID TUMORS 165
AMAL LMBULGODA, DANIEL Y. C. HENG AND CHRISTIAN KOLLMANNSBERGER
1 STRUCTURE AND MECHANISM OF ACTION 166
2 PRECLINICAL DATA 166
3 CLINICAL DATA 167
3.1 RENAL CELL CARCINOMA 167
3.2 GASTROINTESTINAL STROMAL TUMORS 170
3.3 PANCREATIC NEUROENDOCRINE TUMORS 172
3.4 OTHER SOLID TUMORS 174
4 TOXICITY 175
5 DRUG INTERACTIONS 178
6 BIOMARKERS 178
CONTENTS XI
7 SUMMARY AND PERSPECTIVES 179
REFERENCES 179
REGORAFENIB 185
THOMAS J. ETTRICH AND THOMAS SEUFFERLEIN
1 STRUCTURE, MECHANISM OF ACTION, AND PHARMACOKINETICS 186
1.1 MECHANISM OF ACTION 186
1.2 PHARMACOKINETICS AND ELIMINATION 186
1.3 REGORAFENIB IN RENAL OR HEPATIC IMPAIRMENT 187
2 PRECLINICAL DATA 187
3 CLINICAL DATA 188
3.1 REGORAFENIB IN METASTATIC COLORECTAL CANCER 188
3.2 REGORAFENIB IN METASTATIC GASTROINTESTINAL STROMAL TUMORS. . 189
3.3 REGORAFENIB IN HEPATOCELLULAR CARCINOMA 191
3.4 REGORAFENIB IN METASTATIC RENAL CELL CARCINOMA 191
3.5 REGORAFENIB IN SOFT TISSUE SARCOMA 192
4 DETAILED ANALYSIS OF TOXICITY 192
4.1 DERMATOLOGICAL TOXICITY 192
4.2 HYPERTENSION, CARDIAC ISCHEMIA, AND INFARCTION 193
4.3 HEPATOTOXICITY 193
4.4 GASTROINTESTINAL PERFORATION OR FISTULA 193
4.5 HEMORRHAGE 193
4.6 EMBRYO-FETAL TOXICITY 194
5 DRUG INTERACTIONS 194
5.1 EFFECT OF STRONG CYP3A4 INDUCERS 194
5.2 EFFECT OF STRONG CYP3A4 INHIBITORS 194
5.3 EFFECT OF REGORAFENIB ON UGT1A1 SUBSTRATES 194
6 BIOMARKERS 194
7 SUMMARY AND PERSPECTIVES 195
REFERENCES 195
CRIZOTINIB 197
DAVID F. HEIGENER AND MARTIN RECK
1 STRUCTURE AND MECHANISM OF ACTION 198
2 PRECLINICAL DATA 198
3 CLINICAL DATA 199
3.1 NSCLC 199
3.2 OTHER ENTITIES 202
4 TOXICITY 202
5 DRUG INTERACTIONS 202
6 BIOMARKERS 203
7 SUMMARY AND PERSPECTIVES 203
REFERENCES 204
XII CONTENTS
CABOZANTINIB: A MET, RET, AND VEGFR2 TYROSINE
KINASE INHIBITOR 207
CARSTEN GRIILLICH
1 INTRODUCTION 208
2 PRECLINICAL PROPERTIES AND PHARMAKOKINETICS 209
3 CLINICAL TRIALS 210
3.1 PHASE I 210
3.2 PHASE III EXAM TRIAL 210
3.3 PHASE II TRIAL IN PROSTATE CANCER 211
4 DISCUSSION 212
REFERENCES 214
VEMURAFENIB 215
CLAUS GARBE, SAIL ABUSAIF AND THOMAS K. EIGENTLER
1 INTRODUCTION 216
2 STRUCTURE AND MECHANISM OF ACTION 217
3 PRECLINICAL DATA 218
4 PHARMACOKINETICS AND DRUG INTERACTIONS 218
5 VEMURAFENIB IN MELANOMA 219
6 TOXICITY 220
7 VEMURAFENIB IN COLORECTAL CANCER 221
8 VEMURAFENIB IN PAPILLARY THYROID CANCER 221
9 VEMURAFENIB IN NON-SMALL-CELL LUNG CANCER 222
10 VEMURAFENIB IN HAIRY CELL LEUKAEMIA 222
11 BIOMARKERS AND MONITORING OF VEMURAFENIB TREATMENT 222
12 SUMMARY AND PERSPECTIVES 223
REFERENCES 223
DABRAFENIB 227
RADHIKA KAINTHLA, KEVIN B. KIM AND GERALD S. FALCHOOK
1 INTRODUCTION 228
2 MECHANISM OF ACTION 228
3 PRECLINICAL DATA 229
3.1 DABRAFENIB ACTIVITY IN V600 BRAF-MUTANT CELL LINES 229
3.2 DABRAFENIB AND IMMUNE MODULATION 230
3.3 MECHANISMS OF DABRAFENIB RESISTANCE 230
4 METASTATIC MELANOMA 232
4.1 MONOTHERAPY 232
4.2 MONOTHERAPY IN BRAIN METASTASIS 233
4.3 COMBINATION THERAPY WITH TRAMETINIB 234
CONTENTS XJIJ
5 OTHER CANCERS WITH V600E BRAF MUTATIONS 235
5.1 DABRAFENIB MONOTHERAPY 235
5.2 COMBINATION THERAPY WITH TRAMETINIB
IN COLORECTAL CANCER (CRC) 235
6 TOXICITY 236
7 DRUG INTERACTIONS 236
8 BIOMARKERS 237
8.1 PREDICTORS OF RESPONSE 237
8.2 PHARMACODYNAMIC MARKERS 237
9 SUMMARY AND PERSPECTIVES 237
REFERENCES 238
TRAMETINIB 241
ROBERT ZEISER
1 STRUCTURE AND MECHANISM OF ACTION 242
2 PRECLINICAL DATA 242
3 CLINICAL DATA 244
4 TOXICITY 245
5 DRUG INTERACTIONS 246
6 BIOMARKERS 246
7 SUMMARY AND PERSPECTIVES 247
REFERENCES 247
RUXOLITINIB 249
HEIKO BECKER, MONIKA ENGELHARDT, NIKOLAS VON BUBNOFF
AND RALPH WASCH
1 STRUCTURE AND MECHANISM OF ACTION 250
2 PRECLINICAL DATA 250
3 CLINICAL DATA 251
4 TOXICITY 254
5 DRUG INTERACTIONS 255
6 BIOMARKERS 256
7 SUMMARY AND PERSPECTIVES 256
REFERENCES 256
IBRUTINIB 259
MARK-ALEXANDER SCHWARZBICH AND MATTHIAS WITZENS-HARIG
1 STRUCTURE AND MECHANISM OF ACTION 260
2 PRECLINICAL DATA 262
3 CLINICAL DATA 263
4 TOXICITY 264
5 DRUG INTERACTIONS 265
6 SUMMARY AND PERSPECTIVES 265
REFERENCES 265
XIV CONTENTS
DECITABINE 269
BJORN HACKANSON AND MICHAEL DASKALAKIS
1 INTRODUCTION 270
2 STRUCTURE AND MECHANISM OF ACTION 271
2.1 SINGLE-AGENT DECITABINE IN MDS AND AML 271
2.2 COMBINATION TREATMENT WITH DECITABINE
IN MDS AND AML 275
2.3 DECITABINE AS A PREPARATIVE AGENT FOR ALLOGENEIC
STEM CELL TRANSPLANTATION 278
2.4 IMMUNOMODULATION WITH DECITABINE 279
2.5 DECITABINE TREATMENT IN OTHER DISEASES 281
3 TOXICITY 286
4 DRUG INTERACTIONS 287
5 BIOMARKERS 287
6 SUMMARY AND PERSPECTIVES 287
REFERENCES 288
5-AZACYTIDINE/5-AZACITIDINE 299
ANTONIA M. S. MIILLER AND MAREIKE FLOREK
1 INTRODUCTION 300
2 STRUCTURE AND MECHANISM OF ACTION 301
2.1 STRUCTURE 301
2.2 MECHANISM OF ACTION 301
2.3 PHARMACOLOGY, BIOAVAILABILITY, HALF-LIFE, ELIMINATION,
DRUG-DRUG INTERACTIONS 302
3 TOXICITY 303
3.1 SAFETY, SIDE EFFECTS, AND CONTRAINDICATIONS 303
4 PRECLINICAL DATA 305
5 CLINICAL USE OF 5-AZACYTIDINE 306
5.1 EARLY STUDIES 306
5.2 RANDOMIZED PHASE III STUDIES OF 5-AZACYTIDINE 307
5.3 CURRENT QUESTIONS AND PRELIMINARY RESULTS 310
6 CONCLUSION AND PERSPECTIVE 317
REFERENCES 318
BORTEZOMIB 325
HERMANN EINSELE
1 MODE OF ACTION 326
2 ANTITUMOR EFFECTS 327
3 CLINICAL APPLICATION OF PROTEASOME INHIBITORS 329
4 BORTEZOMIB 330
5 BORTEZOMIB-BASED COMBINATION THERAPY FOR MULTIPLE MYELOMA . 332
6 TREATMENT OPTIONS FOR PATIENTS ELIGIBLE FOR TRANSPLANT 333
7 NEXT-GENERATION PROTEASOME INHIBITORS 335
REFERENCES 337
CONTENTS XV
LENALIDOMIDE 347
KATJA WEISEL AND LOTHAR KANZ
1 INTRODUCTION 348
2 STRUCTURE AND MECHANISM OF ACTION 348
3 CLINICAL DATA 349
4 LENALIDOMIDE IN MULTIPLE MYELOMA 349
5 LENALIDOMIDE IN RELAPSED MULTIPLE MYELOMA 350
6 LENALIDOMIDE IN NEWLY DIAGNOSED MULTIPLE MYELOMA 350
7 MAINTENANCE TREATMENT WITH LENALIDOMIDE IN MULTIPLE
MYELOMA AFTER ASCT 351
8 LENALIDOMIDE IN MDS 352
9 LENALIDOMIDE IN OTHER HEMATOLOGICAL MALIGNANCIES 353
10 LENALIDOMIDE IN SOLID TUMORS 354
11 CONCLUSIONS AND FUTURE PERSPECTIVES 355
REFERENCES 355
POMALIDOMIDE 359
MONIKA ENGELHARDT, RALPH WASCH, HEIKE REINHARDT AND MARTINA KLEBER
1 STRUCTURE AND MECHANISM OF ACTION 360
2 PRECLINICAL DATA 361
3 CLINICAL DATA 364
4 MM 364
5 AL AMYLOIDOSIS 367
6 MYELOFIBROSIS 367
7 TOXICITY 368
8 DRUG INTERACTIONS 369
9 BIOMARKERS 369
10 SUMMARY AND PERSPECTIVES 370
REFERENCES 370
EVEROLIMUS 373
JENS HASSKARL
1 INTRODUCTION 374
2 STRUCTURE AND MECHANISM OF ACTION 376
3 PRECLINICAL DATA 376
4 CLINICAL DATA 377
4.1 PHARMACOKINETICS AND PHARMACODYNAMICS 377
4.2 CLINICAL DEVELOPMENT OF EVEROLIMUS 378
5 TOXICITY 387
6 DRUG INTERACTIONS 387
7 BIOMARKERS 387
8 SUMMARY AND PERSPECTIVES 388
REFERENCES 388
XVI CONTENTS
TEMSIROLIMUS 393
MICHAEL SCHULZE, CHRISTIAN STOCK, MASSIMO ZACCAGNINI,
DOGU TEBER AND JENS J. RASSWEILER
1 INTRODUCTION 394
2 DEVELOPMENT 395
3 STRUCTURE AND MECHANISM OF ACTION 395
4 CLINICAL DATA 397
5 SAFETY AND EFFICACY 397
6 SIDE EFFECTS 399
7 CONCLUSION AND FUTURE PERSPECTIVES 400
REFERENCES 401
VISMODEGIB 405
F. MEISS AND R. ZEISER
1 INTRODUCTION 406
2 STRUCTURE AND MECHANISM OF ACTION 407
2.1 STRUCTURE 407
2.2 MECHANISM OF ACTION 407
3 PRECLINICAL DATA 408
4 CLINICAL DATA 408
4.1 VISMODEGIB IN BASAL CELL CARCINOMA (BCC) 408
4.2 VISMODEGIB IN COLORECTAL CANCER 410
4.3 VISMODEGIB IN OVARIAN CANCER 410
4.4 VISMODEGIB IN SMALL LUNG CELL CANCER 411
4.5 VISMODEGIB IN HEMATOLOGIC DISEASES 411
4.6 VISMODEGIB IN MEDULLOBLASTOMA 412
5 TOXICITY 412
6 DRUG INTERACTIONS 414
7 SUMMARY AND PERSPECTIVES 414
REFERENCES 415 |
| any_adam_object | 1 |
| author2 | Martens, Uwe Marc 1966- |
| author2_role | edt |
| author2_variant | u m m um umm |
| author_GND | (DE-588)132250608 |
| author_facet | Martens, Uwe Marc 1966- |
| building | Verbundindex |
| bvnumber | BV041857715 |
| classification_rvk | XI 7000 |
| ctrlnum | (OCoLC)881372331 (DE-599)DNB1047007568 |
| dewey-full | 616.994061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994061 |
| dewey-search | 616.994061 |
| dewey-sort | 3616.994061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 2. ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 cb4500</leader><controlfield tag="001">BV041857715</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20140627</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">140521s2014 gw ad|| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">14,N06</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1047007568</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3642544894</subfield><subfield code="9">3-642-54489-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783642544897</subfield><subfield code="c">Gb. : ca. EUR 149.79 (DE) (freier Pr.), ca. EUR 153.99 (AT) (freier Pr.), ca. sfr 186.50 (freier Pr.)</subfield><subfield code="9">978-3-642-54489-7</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783642544897</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">Best.-Nr.: 86236875</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)881372331</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1047007568</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994061</subfield><subfield code="2">22/ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 7000</subfield><subfield code="0">(DE-625)153024:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Small molecules in oncology</subfield><subfield code="c">Uwe M. Martens ed.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">2. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin [u.a.]</subfield><subfield code="b">Springer</subfield><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVI, 417 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield><subfield code="c">24 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Recent results in cancer research</subfield><subfield code="v">201</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Kleines Molekül</subfield><subfield code="0">(DE-588)4164124-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Kleines Molekül</subfield><subfield code="0">(DE-588)4164124-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martens, Uwe Marc</subfield><subfield code="d">1966-</subfield><subfield code="0">(DE-588)132250608</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield><subfield code="z">978-3-642-54490-3</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Recent results in cancer research</subfield><subfield code="v">201</subfield><subfield code="w">(DE-604)BV000000043</subfield><subfield code="9">201</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">X:MVB</subfield><subfield code="q">text/html</subfield><subfield code="u">http://deposit.dnb.de/cgi-bin/dokserv?id=4582318&prov=M&dok_var=1&dok_ext=htm</subfield><subfield code="3">Inhaltstext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=027302021&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-027302021</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV041857715 |
| illustrated | Illustrated |
| indexdate | 2024-09-10T01:15:04Z |
| institution | BVB |
| isbn | 3642544894 9783642544897 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-027302021 |
| oclc_num | 881372331 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-29 DE-19 DE-BY-UBM |
| owner_facet | DE-355 DE-BY-UBR DE-29 DE-19 DE-BY-UBM |
| physical | XVI, 417 S. Ill., graph. Darst. 24 cm |
| publishDate | 2014 |
| publishDateSearch | 2014 |
| publishDateSort | 2014 |
| publisher | Springer |
| record_format | marc |
| series | Recent results in cancer research |
| series2 | Recent results in cancer research |
| spelling | Small molecules in oncology Uwe M. Martens ed. 2. ed. Berlin [u.a.] Springer 2014 XVI, 417 S. Ill., graph. Darst. 24 cm txt rdacontent n rdamedia nc rdacarrier Recent results in cancer research 201 Cytostatikum (DE-588)4068347-3 gnd rswk-swf Kleines Molekül (DE-588)4164124-3 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Cytostatikum (DE-588)4068347-3 s Kleines Molekül (DE-588)4164124-3 s DE-604 Martens, Uwe Marc 1966- (DE-588)132250608 edt Erscheint auch als Online-Ausgabe 978-3-642-54490-3 Recent results in cancer research 201 (DE-604)BV000000043 201 X:MVB text/html http://deposit.dnb.de/cgi-bin/dokserv?id=4582318&prov=M&dok_var=1&dok_ext=htm Inhaltstext DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=027302021&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Small molecules in oncology Recent results in cancer research Cytostatikum (DE-588)4068347-3 gnd Kleines Molekül (DE-588)4164124-3 gnd |
| subject_GND | (DE-588)4068347-3 (DE-588)4164124-3 (DE-588)4143413-4 |
| title | Small molecules in oncology |
| title_auth | Small molecules in oncology |
| title_exact_search | Small molecules in oncology |
| title_full | Small molecules in oncology Uwe M. Martens ed. |
| title_fullStr | Small molecules in oncology Uwe M. Martens ed. |
| title_full_unstemmed | Small molecules in oncology Uwe M. Martens ed. |
| title_short | Small molecules in oncology |
| title_sort | small molecules in oncology |
| topic | Cytostatikum (DE-588)4068347-3 gnd Kleines Molekül (DE-588)4164124-3 gnd |
| topic_facet | Cytostatikum Kleines Molekül Aufsatzsammlung |
| url | http://deposit.dnb.de/cgi-bin/dokserv?id=4582318&prov=M&dok_var=1&dok_ext=htm http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=027302021&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000000043 |
| work_keys_str_mv | AT martensuwemarc smallmoleculesinoncology |